Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies

References

• Brownlee M Biochemistry and molecular cell biology of diabetic complications Nature 2001 414 6865 813 820 11742414
   PubMed Web of Science ®Google Scholar
• Brunner EJ Shipley MJ Witte DR Fuller JH Marmot MG Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study Diabetes Care 2006 29 1 26 31 16373891
   PubMed Web of Science ®Google Scholar
• DECODE Study Group. European Diabetes Epidemiology Group Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe (DECODE). Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria Lancet 1999 354 9179 617 621 10466661
   PubMed Web of Science ®Google Scholar
• Sattar N Gaw A Scherbakova O Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study Circulation 2003 108 4 414 419 12860911
   PubMed Web of Science ®Google Scholar
• Stratton IM Adler AI Neil HA Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 2000 321 7258 405 412 10938048
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trial (DCCT) Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 1993 329 14 977 986 8366922
   PubMed Web of Science ®Google Scholar
• Hanley AJ Williams K Stern MP Haffner SM Homeostasis model assessment of insulin resistance in relation to the incidence of cardio-vascular disease: the San Antonio Heart Study Diabetes Care 2002 25 7 1177 1184 12087016
   PubMed Web of Science ®Google Scholar
• Yusuf S Sleight P Pogue J Bosch J Davies R Dagenais G Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 2000 342 3 145 153 10639539
   PubMed Web of Science ®Google Scholar
• Dagenais GR Yi Q Mann JF Bosch J Pogue J Yusuf S Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease Am Heart J 2005 149 1 54 60 15660034
   PubMed Web of Science ®Google Scholar
• Smith NL Barzilay JI Shaffer D Fasting and 2-hour postchallenge serum glucose measures and risk of incident cardiovascular events in the elderly: the Cardiovascular Health Study Arch Intern Med 2002 162 2 209 216 11802755
   PubMedGoogle Scholar
• Hu FB Stampfer MJ Haffner SM Solomon CG Willett WC Manson JE Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes Diabetes Care 2002 25 7 1129 1134 12087009
   PubMed Web of Science ®Google Scholar
• Khaw KT Wareham N Bingham S Luben R Welch A Day N Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk Ann Intern Med 2004 141 6 413 420 15381514
   PubMed Web of Science ®Google Scholar
• Haffner SM Lehto S Rönnemaa T Pyörälä K Laakso M Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 1998 339 4 229 234 9673301
   PubMed Web of Science ®Google Scholar
• Gæde P Lund-Andersen H Parving HH Pedersen O Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med 2008 358 6 580 591 18256393
   PubMed Web of Science ®Google Scholar
• Capes SE Hunt D Malmberg K Gerstein HC Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview Lancet 2000 355 9206 773 778 10711923
   PubMed Web of Science ®Google Scholar
• Muhlestein JB Anderson JL Horne BD for the Intermountain Heart Collaborative Study Group Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention Am Heart J 2003 146 2 351 358 12891207
   PubMed Web of Science ®Google Scholar
• Norhammar A Tenerz A Nilsson G Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study Lancet 2002 359 9324 2140 2144 12090978
   PubMed Web of Science ®Google Scholar
• Kosiborod M Inzucchi SE Krumholz HM Glucose normalization and outcomes in patients with acute myocardial infarction Arch Intern Med 2009 169 5 438 446 19273773
   PubMedGoogle Scholar
• Finfer S Chittock DR Su SY for NICE-SUGAR Study Investigators Intensive versus conventional glucose control in critically ill patients N Engl J Med 2009 360 13 1283 1297 19318384
   PubMed Web of Science ®Google Scholar
• Inzucchi SE Siegel MD Glucose control in the ICU – how tight is too tight? N Engl J Med 2009 360 13 1346 1349 19318385
   PubMed Web of Science ®Google Scholar
• United Kingdom Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 1998 352 9131 837 853 9742976
   PubMed Web of Science ®Google Scholar
• Skyler JS Bergenstal R Bonow RO Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association Diabetes Care 2009 32 1 187 192 19092168
   PubMed Web of Science ®Google Scholar
• Holman RR Paul SK Bethel MA Matthews DR Neil HA 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 2008 359 15 1577 1589 18784090
   PubMed Web of Science ®Google Scholar
• Duckworth W Abraira C Moritz T Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 2009 360 2 129 139 19092145
   PubMed Web of Science ®Google Scholar
• Patel A MacMahon S Chalmers J for the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release and Controlled Evaluation (ADVANCE) Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 2008 358 24 2560 2572 18539916
   PubMed Web of Science ®Google Scholar
• Gerstein HC Miller ME Byington RP for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 2008 358 24 2545 2559 18539917
   PubMed Web of Science ®Google Scholar
• Ray KK Seshasai SR Wijesuriya S Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials Lancet 2009 373 9677 1765 1772 19465231
   PubMed Web of Science ®Google Scholar
• Mannucci E Monami M Lamanna C Gori F Marchionni N Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials Nutr Metab Cardiovasc Dis 2009 19 9 604 612 19427768
   PubMed Web of Science ®Google Scholar
• Currie CJ Peters JR Tynan A Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study Lancet 2010 375 9713 481 489 20110121
   PubMed Web of Science ®Google Scholar
• del Prato S Megatrials in type 2 diabetes. From excitement to frustration? Diabetologia 2009 52 7 1219 1226 19373446
   PubMed Web of Science ®Google Scholar
• Rodbard HW Jellinger PS Davidson JA Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control Endocr Pract 2009 15 6 540 559 19858063
   PubMed Web of Science ®Google Scholar
• Haffner SM Relationship of metabolic risk factors and development of cardiovascular disease and diabetes Obesity (Silver Spring) 2006 14 Suppl 3 S121 S127
   Web of Science ®Google Scholar
• DeFronzo RA Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus Diabetes 2009 58 4 773 795 19336687
   PubMed Web of Science ®Google Scholar
• Nathan DM Buse JB Davidson MB Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy Diabetes Care 2009 32 1 193 203 18945920
   PubMed Web of Science ®Google Scholar
• Wajchenberg BL Beta-cell failure in diabetes and preservation by clinical treatment Endocr Rev 2007 28 2 187 218 17353295
   PubMed Web of Science ®Google Scholar
• Rao AD Kuhadiya N Reynolds K Fonseca VA Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of observational studies Diabetes Care 2008 31 8 1672 1678 18458139
   PubMed Web of Science ®Google Scholar
• Nauck MA Homberger E Siegel EG Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses J Clin Endocrinol Metab 1986 63 2 492 498 3522621
   PubMed Web of Science ®Google Scholar
• Nauck MA Unraveling the science of incretin biology Am J Med 2009 122 Suppl 6 S3 S10 19464426
   PubMed Web of Science ®Google Scholar
• Girard J The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions Diabetes Metab 2008 34 6 Pt 1 550 559 19036624
   PubMed Web of Science ®Google Scholar
• Drucker DJ The biology of incretin hormones Cell Metab 2006 3 3 153 165 16517403
   PubMed Web of Science ®Google Scholar
• Toft-Nielsen MB Damholt MB Madsbad S Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients J Clin Endocrinol Metab 2001 86 8 3717 3723 11502801
   PubMed Web of Science ®Google Scholar
• Vilsbøll T Knop FK Krarup T The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype J Clin Endocrinol Metab 2003 88 10 4897 4903 14557471
   PubMed Web of Science ®Google Scholar
• Zander M Madsbad S Madsen JL Holst JJ Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study Lancet 2002 359 9309 824 830 11897280
   PubMed Web of Science ®Google Scholar
• Rachman J Barrow BA Levy JC Turner RC Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM Diabetologia 1997 40 2 205 211 9049482
   PubMed Web of Science ®Google Scholar
• Nauck MA Kleine N Orskov C Holst JJ Willms B Creutzfeldt W Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patients Diabetologia 1993 36 8 741 744 8405741
   PubMed Web of Science ®Google Scholar
• Hinke SA Hellemans K Schuit F Plasticity of the β cell insulin secretory competence: preparing the pancreatic β cell for the next meal J Physiol 2004 558 Pt 2 369 380 15181163
   PubMed Web of Science ®Google Scholar
• Henquin JC Triggering and amplifying pathways of regulation of insulin secretion by glucose Diabetes 2000 49 11 1751 1760 11078440
   PubMed Web of Science ®Google Scholar
• Henquin JC Pathways in β-cell stimulus-secretion coupling as targets for therapeutic insulin secretagogues Diabetes 2004 53 Suppl 3 S48 S58 15561921
   PubMed Web of Science ®Google Scholar
• Gillison S Bartlett ST Curry D Inhibition by cyclosporine of insulin secretion – a β cell-specific alteration of islet tissue function Transplantation 1991 52 5 890 895 1683035
   PubMed Web of Science ®Google Scholar
• Van Raalte DH Ouwens DM Diamant M Novel insights into glucocorticoid-meidated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest 2009 39 2 81 93 19200161
   PubMed Web of Science ®Google Scholar
• Drucker DJ Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis Endocrinology 2003 144 12 5145 5148 14645210
   PubMed Web of Science ®Google Scholar
• Ritzel RA Therapeutic approaches based on beta-cell mass preservation and/or regeneration Front Biosci 2009 14 1835 1850 19273167
   PubMed Web of Science ®Google Scholar
• Li Y Cao X Li LX Brubaker PL Edlund H Drucker DJ Beta-cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1 Diabetes 2005 54 2 482 491 15677506
   PubMed Web of Science ®Google Scholar
• Ranta F Avram D Berchtold S Dexamethasone induces cell death in insulin-secreting cells, an effect reversed by exendin-4 Diabetes 2006 55 5 1380 1390 16644695
   PubMed Web of Science ®Google Scholar
• D’Amico E Hui H Khoury N Di Mario U Perfetti R Pancreatic beta-cells expressing GLP-1 are resistant to the toxic effects of immunosuppressive drugs J Mol Endocrinol 2005 34 2 377 390 15821104
   PubMed Web of Science ®Google Scholar
• Lambillotte C Gilon P Henquin JC Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets J Clin Invest 1997 99 3 414 423 9022074
   PubMed Web of Science ®Google Scholar
• Meier JJ Weyhe D Michaely M Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes Crit Care Med 2004 32 3 848 851 15090972
   PubMed Web of Science ®Google Scholar
• Bunck MC Diamant M Corner A One-year treatment with exenatide improves β-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients Diabetes Care 2009 32 5 762 768 19196887
   PubMed Web of Science ®Google Scholar
• Klonoff DC Buse JB Nielsen LL Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years Curr Med Res Opin 2008 24 1 275 286 18053320
   PubMed Web of Science ®Google Scholar
• Schwartz S TZDs in combination with incretins: synergy in diabetes treatment Rev Endocrinol 2008 11 37 44
   Google Scholar
• Kohl BA Schwartz S Surgery in the patient with endocrine dysfunction Med Clin North Am 2009 93 5 1031 1047 19665618
   PubMed Web of Science ®Google Scholar
• Ban K Noyan-Ashraf MH Hoefer J Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways Circulation 2008 117 18 2340 2350 18427132
   PubMed Web of Science ®Google Scholar
• Sulistio M Carothers C Mangat M Lujan M Oliveros R Chilton R GLP-1 agonist-based therapies: an emerging new class of antidiabetic drug with potential cardioprotective effects Curr Atheroscler Rep 2009 11 2 93 99 19228481
   PubMed Web of Science ®Google Scholar
• Nyström T Gonon AT Sjöholm A Pernow J Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism Regul Pept 2005 125 1–3 173 177 15582729
   PubMedGoogle Scholar
• Nikolaidis LA Mankad S Sokos GG Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion Circulation 2004 109 8 962 965 14981009
   PubMed Web of Science ®Google Scholar
• Sokos GG Nikolaidis LA Mankad S Elahi D Shannon RP Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure J Card Fail 2006 12 9 694 699 17174230
   PubMed Web of Science ®Google Scholar
• Sokos GG Bolukoglu H German J Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting J Cardiol 2007 100 5 824 829
   Web of Science ®Google Scholar
• Kim W Egan JM The role of incretins in glucose homeostasis and diabetes treatment Pharmacol Rev 2008 60 4 470 512 19074620
   PubMed Web of Science ®Google Scholar
• Eng J Kleinman WA Singh L Singh G Raufman JP Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas J Biol Chem 1992 267 11 7402 7405 1313797
   PubMed Web of Science ®Google Scholar
• Byetta [package insert] San Diego, CA Amylin Pharmaceuticals, Inc 2009
   Google Scholar
• Buse JB Henry RR Han J Kim DD Fineman MS Baron AD for the Exenatide-113 Clinical Study Group Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes Diabetes Care 2004 27 11 2628 2635 15504997
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Ratner RE Han J Kim DD Fineman MS Baron AD Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Diabetes Care 2005 28 5 1092 1100 15855572
   PubMed Web of Science ®Google Scholar
• Kendall DM Riddle MC Rosenstock J Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea Diabetes Care 2005 28 5 1083 1091 15855571
   PubMed Web of Science ®Google Scholar
• Blonde L Klein EJ Han J Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes Diabetes Obes Metab 2006 8 4 436 447 16776751
   PubMed Web of Science ®Google Scholar
• Heine RJ Van Gaal LF Johns D Mihm MJ Widel MH Brodows RG Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial Ann Intern Med 2005 143 8 559 569 16230722
   PubMed Web of Science ®Google Scholar
• Nauck MA Duran S Kim D A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study Diabetologia 2007 50 2 259 267 17160407
   PubMed Web of Science ®Google Scholar
• Barnett AH Burger J Johns D Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial Clin Ther 2007 29 11 2333 2348 18158075
   PubMed Web of Science ®Google Scholar
• Bhushan R Elkind-Hirsch KE Bhushan M Butler WJ Duncan K Marrioneaux O Exenatide use in the management of metabolic syndrome: a retrospective database study Endocr Pract 2008 14 8 993 999 19095598
   PubMedGoogle Scholar
• Bunck MC Corner A Eliasson B One year exenatide therapy, compared with insulin glargine, reduces postprandial oxidative stress in metformin-treated patients with type 2 diabetes Diabetes 2009 58 Suppl 1 A147 [Abstract 548-P]
   Google Scholar
• Bunck MC Diamant M Eliasson B Beneficial changes on body composition and circulating adiponectin and hsCRP levels following one year of exenatide therapy, compared with insulin glargine, in metformin-treated patients with type 2 diabetes Diabetes 2009 58 Suppl 1 A125 [Abstract 469-P]
   Google Scholar
• Gentilella R Bianchi C Rossi A Rotella CM Exenatide: a review from pharmacology to clinical practice Diabetes Obes Metab 2009 11 6 544 556 19383034
   PubMed Web of Science ®Google Scholar
• Shen L Han J Yushmanova I Bruce S Porter L Cardiovascular safety of exenatide BID: an integrated analysis from long-term controlled clinical trials in subjects with type 2 diabetes Diabetes 2009 58 Suppl 1 A96 A97 [Abstract 366-OR]
   Google Scholar
• Best JH Herman WH Wintle M Estimating the potential cardiovascular benefit of A1c reduction and weight loss in patients with type 2 diabetes treated with exenatide for at least 3 years Diabetes 2009 58 Suppl 1 A316 [Abstract 1202-P]
   Google Scholar
• Fineman MS Shen LZ Taylor K Baron AD Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting effects in subjects with type 2 diabetes Diabetes Metab Res Rev 2004 20 5 411 417 15343588
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Okerson T Viswanathan P Guan X Holcombe JH MacConell L Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study Curr Med Res Opin 2008 24 10 2943 2952 18786299
   PubMed Web of Science ®Google Scholar
• Bruce S MacConell L Brown C Safety and tolerability of exenatide BID in patients with type 2 diabetes: integrated analysis of 3854 patients from 11 comparator controlled clinical trials Diabetes 2009 58 Suppl 1 A155 A156 [Abstract 578-P]
   Google Scholar
• Bloomgren G Dore D Patterson R Noel R Braun D Seeger J Incidence of acute pancreatitis in exenatide initiators compared to other antidiabetic drug initiators: a retrospective, cohort study Diabetes 2009 58 Suppl 1 A41 [Abstract 158-OR]
   Google Scholar
• Bergenstal RM Kim T Trautmann M Zhuang D Okerson T Taylor K Exenatide once weekly elicited improvements in blood pressure and lipid profile over 52 weeks in patients with type 2 diabetes Circulation 2008 118 Suppl 1 1086 [Abstract 1239]
   Google Scholar
• Drucker DJ Buse JB Taylor K for the DURATION-1 Study Group Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Lancet 2008 372 9645 1240 1250 18782641
   PubMed Web of Science ®Google Scholar
• Nauck M Frid A Hermansen K for the LEAD-2 Study Group Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study Diabetes Care 2009 32 1 84 90 18931095
   PubMed Web of Science ®Google Scholar
• Russell-Jones D Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue Mol Cell Endocrinol 2009 297 1–2 137 140 19041364
   PubMed Web of Science ®Google Scholar
• Victoza (liraglutide) [package insert] Princeton, NJ Novo Nordisk Inc 2010
   Google Scholar
• Garber A Henry R Ratner R for the LEAD-3 Mono Study Group Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial Lancet 2009 373 9662 473 481 18819705
   PubMed Web of Science ®Google Scholar
• Madsbad S Liraglutide effect and action in diabetes (LEAD) trial Expert Rev Endocrinol Metab 2009 4 2 119 129
   PubMedGoogle Scholar
• Marre M Shaw J Brändle M for the LEAD-1 SU Study Group Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) Diabet Med 2009 26 3 268 278 19317822
   PubMed Web of Science ®Google Scholar
• Zinman B Gerich J Buse JB for the LEAD-4 Study Investigators Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD) Diabetes Care 2009 32 7 1224 1230 19289857
   PubMed Web of Science ®Google Scholar
• Buse JB Rosenstock J Sesti G for the LEAD-6 Study Group Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Lancet 2009 374 9683 39 47 19515413
   PubMed Web of Science ®Google Scholar
• Courrèges JP Vilsbøll T Zdravkovic M Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes Diabet Med 2008 25 9 1129 1131 19183322
   PubMed Web of Science ®Google Scholar
• Sullivan SD Alfonso-Cristancho R Conner C Hammer M Blonde L Improvement in cardiovascular risk factors and long-term outcomes in people with T2D treated with liraglutide or glimepiride monotherapy Diabetes 2009 58 Suppl 1 A595 [Abstract 2308-PO]
   Google Scholar
• Zinman B Buse J Falahati A Moses A Gough S Liraglutide more effectively achieves a composite endpoint for A1C, SBP and weight change than other diabetes therapies Diabetes 2009 58 Suppl 1 A143 A144 [Abstract 537-P]
   Google Scholar
• Fonseca V Madsbad S Falahati A Zychma MJ Plutzky J Once-daily human GLP-1 analog liraglutide reduces systolic BP – a meta-analysis of six clinical trials (LEAD) Diabetes 2009 58 Suppl 1 A146 [Abstract 545-P]
   PubMed Web of Science ®Google Scholar
• Nauck MA Ratner RE Kapitza C Berria R Boldrin M Balena R Treatment with the human once-weekly GLP-1 analogue taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes mellitus inadequately controlled with metformin alone: a double-blind placebo-controlled study Diabetes Care 2009 32 7 1237 1243 19366970
   PubMed Web of Science ®Google Scholar
• Matthews JE Stewart MW De Boever EH for the Albiglutide Study Group Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes J Clin Endocrinol Metab 2008 93 12 4810 4817 18812476
   PubMed Web of Science ®Google Scholar
• Herman GA Stevens C Van Dyck K Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses Clin Pharmacol Ther 2005 78 6 675 688 16338283
   PubMed Web of Science ®Google Scholar
• Raz I Hanefeld M Xu L Caria C Williams-Herman D Khatami H for the Sitagliptin Study 023 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus Diabetologia 2006 49 11 2564 2571 17001471
   PubMed Web of Science ®Google Scholar
• Goldstein BJ Feinglos MN Lunceford JK Johnson J Williams-Herman DE for the Sitagliptin 036 Study Group Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes Diabetes Care 2007 30 8 1979 1987 17485570
   PubMed Web of Science ®Google Scholar
• Hermansen K Kipnes M Luo E Fanurik D Khatami H Stein P for the Sitagliptin Study 035 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin Diabetes Obes Metab 2007 9 5 733 745 17593236
   PubMed Web of Science ®Google Scholar
• Wolf R Frederich R Fiedorek F Evaluation of CV risk in the saxagliptin clinical trials Presented at the American Diabetes Association, 69th scientific sessions 2009 June 5–9 New Orleans, LA LB3 [Abstract 8-LB]. Available from: http://professional.diabetes.org/UserFiles/File/Scientific%20Sessions/2009/Abstracts/LB%20Abstracts/09%20ADA%20-%20Late%20Breaking%20Handout(1).pdf Accessed Jan 12, 2010
   Google Scholar
• DeFronzo RA Fleck PR Wilson CA Mekki Q for the Alogliptin Study 010 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study Diabetes Care 2008 31 12 2315 2317 18809631
   PubMed Web of Science ®Google Scholar
• Amori RE Lau J Pittas AG Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis JAMA 2007 298 2 194 206 17622601
   PubMed Web of Science ®Google Scholar
• Campbell RK White JRJr More choices than ever before: emerging therapies for type 2 diabetes Diabetes Educ 2008 34 3 518 534 18535325
   PubMed Web of Science ®Google Scholar
• McIntosh CH Dipeptidyl peptidase IV inhibitors and diabetes therapy Front Biosci 2008 13 1753 1773 17981665
   PubMed Web of Science ®Google Scholar
• Williams-Herman D Round E Swern AS Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis BMC Endocr Disord 2008 8 14 18954434
   PubMedGoogle Scholar
• US Food and Drug Administration Information for healthcare professionals – acute pancreatitis and sitagliptin (marketed as Januvia and Janumet) 2009 9 25 Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm183764.htm Accessed March 17, 2010
   Google Scholar